Close Menu

NEW YORK (GenomeWeb) – Adaptive Biotechnologies plans to collaborate with Amgen to develop and commercialize Adaptive's next-generation sequencing-based immune profiling assay, ClonoSeq, to assess minimal residual disease in patients with acute lymphoblastic leukemia, Adaptive said today.

As part of the collaboration, the companies plan to collect MRD data in order to establish validated thresholds of residual disease that can predict patient outcomes in ALL.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.